
Opinion|Videos|October 14, 2024
Impact of Adjuvant Immunotherapy on First-Line Treatment Decisions for Newly Diagnosed mRCC
Author(s)Rana R. McKay, MD
Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for patients with newly diagnosed metastatic renal cell carcinoma.
Advertisement
Episodes in this series

- Please discuss how the introduction of adjuvant immunotherapy has impacted your first-line treatment decisions for patients with newly diagnosed metastatic renal cell carcinoma?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















